Background: Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported. Case presentation: We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months. Conclusion: This case suggests new perspectives for the treatment of asbestosis and its systemic features.
CITATION STYLE
Niccoli, L., Cassarà, E., Kaloudi, O., Nannini, C., Romagnoli, M., & Cantini, F. (2015). Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: A case report. BMC Musculoskeletal Disorders, 16(1). https://doi.org/10.1186/s12891-015-0602-6
Mendeley helps you to discover research relevant for your work.